Canaccord Genuity Reiterates a 'Buy' on Avanir Pharmaceuticals (AVNR); Nuedexta Survey: Positive Dx and Prescribing Trends Suggest Continued Growth

Canaccord Genuity reiterates a 'Buy' on Avanir Pharmaceuticals (NASDAQ: AVNR) price target of $6.00.

Canaccord analyst, Ritu Baral, said, "Reiterate rating and price target on Nuedexta steady growth, ultimate commercial potential. Nuedexta is AVNR’s drug for pseudobulbar affect, emotional lability seen with stroke, traumatic brain injury and other neurodegenerative disorders. Launch has been modest but steady, and we see new positive trends in long-term care use. We estimate peak annual sales of $350M US and $300M EU."

For an analyst ratings summary and ratings history on Avanir Pharmaceuticals click here. For more ratings news on Avanir Pharmaceuticals click here.

Shares of Avanir Pharmaceuticals closed at $2.29 yesterday, with a 52 week range of $1.98-$4.80.

---

Discover Wall Street's best ratings calls with the pros - Ratings Insider Elite. Free Trial!

You May Also Be Interested In

• Barclays maintains an 'Equalweight' on Tech Data (TECD); Slight Adjustments on Q1 Results
• Oppenheimer Reiterates an 'Outperform' on MakeMyTrip (MMYT); Updating Estimates Ahead of March Qtr
• Compass Point Maintains a 'Neutral' on PNC Financial (PNC); RBC Addition Positive Offset By Increased Competition in C&I Lending

Create E-mail Alert Related Categories

Analyst Comments

Related Entities

Genuity Capital Markets

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?

Follow StreetInsider.com On Twitter